OVERVIEW

Metastasis and recurrence are the major causes of cancer mortality. Despite recent advances in molecularly targeted and immuno-oncology therapy, treating or preventing cancer recurrence and/or metastasis remains a hugely unmet clinical need. Most existing anti-cancer therapeutics only shrink primary tumors without affecting metastatic ones. Invadopodia (a.k.a. “cellular feet”) are the driving force of invasion, growth, and metastasis of cancer cells in the three-dimensional microenvironments in vivo. Antapodia Therapeutics pioneers the identification of a series of "Master Invadopodial Regulator (MIRs)", which are exclusively expressed by invasive cancer cells and thereby can serve as ideal and safe therapeutic targets. The company develops first-in-class and powerful siRNA therapy and monoclonal antibodies (mAb) to target MIRs, which provides an excitingly new avenue to treating aggressive and metastatic cancers.

LNP-siRNA GENE THERAPY

Many solid tumors, such as liver, breast, and pancreatic cancers, are characterized by a highly dense fibrotic stroma termed “desmoplasia”, which impedes the penetration of most therapeutics. Nanoparticle formulation is a clinically proven strategy to facilitate drug penetration in desmoplastic cancers, such as liposomal doxorubicin in breast cancer and liposomal irinotecan in pancreatic cancer. Lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) therapeutics have recently emerged as a safe and efficient approach in the molecular targeting of disease driver genes such as transthyretin in liver amyloidosis and ALAS1 in acute hepatic porphyria. Antapodia Therapeutics combines the third-generation LNP and a proprietary liver-blocking technology to deliver invadopodia-targeted siRNA to both hepatic and non-hepatic cancers, which show tremendous anti-tumor and anti-metastasis efficacy in various tumor models.

AP-01 (LNP-siRNA)

(HCC, TNBC, SCLC)

MIR-01

AP-02 (LNP-siRNA)

(GAC)

MIR-02 & ligand

AP-03 (mAb)

(CRPC, GAC)

MIR-03